Enrolling Studies
Bladder Cancer:
Altor Bioscience (Immunity Bio) Protocol: QUILT-3.032
– a study for patients with BCG unresponsive high-grade non-muscle invasive bladder cancer
https://clinicaltrials.gov/ct2/show/NCT04142359
Altor Bioscience (Immunity Bio) Protocol: QUILT-2.005
– a study for patients with high-grade non-muscle invasive bladder cancer who have never received BCG treatment
https://clinicaltrials.gov/ct2/show/NCT02138734
Prostate Cancer:
Myovant, Inc. Protocol: REPLACE_CV
– a study for patients being treated with Relugolix or Leuprolide Acetate.
https://classic.clinicaltrials.gov/ct2/show/NCT05605964
Myovant, Inc. Protocol: Registry
– a registry study to collect patient satisfaction and compliance with Orgovyx
https://clinicaltrials.gov/study/NCT05467176
Gregor Diagnostics Protocol: GD001
– a study collecting semen samples in men scheduled for prostate biopsy
https://vimeo.com/813614568
BPH-Benign Prostatic Hyperplasia (Enlarged Prostate):
ProVerum, Inc Protocol: The ProVIDE Study
– a device study for treating enlarged prostate in men age 45 and older.
https://clinicaltrials.gov/ct2/show/NCT05186740
Butterfly Medical Ltd Protocol: CL-BM14-001
– a device study for treating enlarged prostate in men 50-80.
https://clinicaltrials.gov/study/NCT05341661
Urinary Incontinence:
Valencia Technologies Corporation Protocol: The Essence
– a study of an FDA approved device for treating urge incontinence.
https://classic.clinicaltrials.gov/ct2/show/NCT05882318
Bladder Cancer:
EnGene INC Protocol: EG-70 in NMIBC Patients BCG-Unresponsive and High-Risk NMIBC Incompletely Treated With BCG or BCG-Naïve
– a study to test a medication in patients with non-muscle invasive bladder cancer
https://classic.clinicaltrials.gov/ct2/show/NCT04752722
